Search Result

Isoforms Recommended:	CDK9

Results for "

CDK9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (35) Bcl-2 Family (3) BCL6 (1) c-Myc (1) Casein Kinase (2) CDK (146) Cholinesterase (ChE) (1) CMV (4) DNA/RNA Synthesis (1) Dopamine Transporter (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (3) Epigenetic Reader Domain (1) ERK (1) FLT3 (3) Fungal (1) GSK-3 (5) HDAC (1) HIV (5) HSV (1) IRE1 (1) JAK (3) Ligands for Target Protein for PROTAC (4) MEK (2) Molecular Glues (2) NEKs (1) PKC (1) PROTACs (12) Reactive Oxygen Species (1) SARS-CoV (2) Small Interfering RNA (siRNA) (3) Virus Protease (1)
By Research Areas:	Cancer (142) Infection (10) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

158

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124639

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

HY-130850

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

HY-RS02401

CDK9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK9 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK9 Human Pre-designed siRNA Set A CDK9 Human Pre-designed siRNA Set A

HY-RS02402

Cdk9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Mouse Pre-designed siRNA Set A Cdk9 Mouse Pre-designed siRNA Set A

HY-RS02403

Cdk9 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Rat Pre-designed siRNA Set A Cdk9 Rat Pre-designed siRNA Set A

HY-147905

CDK9-IN-18	CDK Apoptosis	Cancer
CDK9-IN-18 is a potent *CDK9* inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-149641

CDK9-IN-29	CDK	Cancer
CDK9-IN-29 (compound Z11) is a potent *CDK9* inhibitor (IC₅₀ = 3.20 nM) with good kinase selectivity. CDK9-IN-29 inhibits cell proliferation and induces apoptosis .

HY-155153

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective *CDK9* inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

HY-157980

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

HY-150562

CDK9-IN-19	CDK	Cancer
CDK9-IN-19 is a highly potent and selective *CDK9* inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .

HY-143585

CDK9-IN-14	CDK	Cancer
CDK9-IN-14 is a potent and selective *CDK9* inhibitor with IC₅₀ of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects .

HY-130852

CDK9-IN-11	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

HY-151984

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

HY-139980

CDK9-IN-13	CDK	Cancer
CDK9-IN-13 (compound 38) is potent and selective *CDK9* inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .

HY-160171

CDK9-IN-31	CDK	Cancer
CDK9-IN-31 (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .

HY-147026

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

HY-13231

CDK9-IN-1 2 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-162619

CDK9-IN-33	Apoptosis CDK	Cancer
CDK9-IN-33 (compound C35) is a potent, selective and orally active *CDK9* inhibitor with IC₅₀ values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .

HY-102039

CDK9-IN-8	CDK	Cancer
CDK9-IN-8 is a highly effective and selective *CDK9* inhibitor with an IC₅₀ of 12 nM.

HY-153426

CDK9-IN-23	CDK	Cancer
CDK9-IN-23 (Example 4) is a *CDK9* inhibitor with an IC₅₀ of <20 nM .

HY-115714

CDK9-IN-12	CDK	Cancer
CDK9-IN-12 displays the optimal *CDK9* inhibitory activity with an IC₅₀ value of 5.41 nM.

HY-147131

CDK9-IN-30	CDK HIV	Infection
CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .

HY-155177

CDK9-IN-27	CDK	Cancer
CDK9-IN-27 (Compound 6a) is a *CDK9* inhibitor (IC₅₀s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC₅₀s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research .

HY-160171A

CDK9-IN-31 dimaleate	CDK	Cancer
CDK9-IN-31 dimaleate (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 dimaleate has the potential to be developed as an anticancer agent .

HY-155844

CDK9-IN-26	CDK	Cancer
CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC₅₀=0.18 μM)。 .

HY-156083

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC CDK9/CycT1 Degrader-1 can be used as a PROTAC* target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

HY-164619

CDK9-IN-34	CDK SARS-CoV	Infection Cancer
CDK9-IN-34 (Compound 1b) is an inhibitor for *CDK9* with an IC₅₀ of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC₅₀ of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC₅₀ of 145.92 μM .

HY-155843

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

HY-168515

CDK9-IN-35	CDK	Cancer
CDK9-IN-35 (compound 10j) is an inhibitor of *CDK9/Cyclin* T1 with an IC₅₀ value of 10.2 nM and against the HCT-116 cell line with an IC₅₀ value of 20 nM .

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .

HY-156296

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

HY-16462

CDK9-IN-2 5 Publications Verification	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-151375

CDK9/10/GSK3β-IN-1	Others	Cancer
CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits HsGSK3β (IC₅₀=59 nM), *HsCDK9/CyclinT* (IC₅₀=64 nM), HsCDK5/p25 (IC₅₀=1.093 µM) and HsCDK2/CyclinA (IC₅₀=1.725 µM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines .

HY-149964

*PROTAC CDK9* degrader-7**	CDK	Cancer
PROTAC CDK9 degrader-7 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

HY-149962

*PROTAC CDK9* degrader-5**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-5 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-149963

*PROTAC CDK9* degrader-6**	CDK	Cancer
PROTAC CDK9 degrader-6 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-115729

*PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC CDK9 ligand-1 is a *CDK9* ligand that can be used in the synthesis of PROTACs.

HY-149870

*PROTAC CDK9* degrader-8**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC₅₀ value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer .

HY-168518

*PROTAC CDK9* degrader-9**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-9 (compound 29) is a highly selective and efficient *CDK9* degrader based on PROTAC technology. PROTAC CDK9 degrader-9 can be used in anti-cancer research .

HY-103628

*PROTAC CDK9* Degrader-1** 1 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and *CDK* as a selective *CDK9* degrader.

HY-115728

*PROTAC CDK9* degrader-4**	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious *CDK9* degrader for targeting transcription regulation.

HY-115729A

*(R)-PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

HY-112811

*PROTAC CDK9* degrader-2**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compound 11c) is a potent and selective *CDK9* degrader based on PROTAC, with an IC₅₀ of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC .

HY-156795

*PROTAC CDK9/CycT1 Degrader-2*	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-147797

*EGFR/HER2/CDK9-IN-2*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .*

HY-147798

*EGFR/HER2/CDK9-IN-3*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .*

HY-147796

*EGFR/HER2/CDK9-IN-1*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .*

HY-148521

*PROTAC FLT3/CDK9* degrader-1**	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-137478A

KB-0742 dihydrochloride	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P2559

CDK7/9 tide	CDK	Cancer
CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1127

Tricin 2 Publications Verification	Infection Structural Classification Flavonoids Classification of Application Fields Flavones Agrostidoideae Source classification Phenols Polyphenols Plants Disease Research Fields Triticum aestivum L.	CMV
Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-103248

Toyocamycin 5 Publications Verification Vengicide	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields Other Antibiotics	IRE1 Fungal Antibiotic Apoptosis CDK
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC₅₀ value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits *CDK9* with an IC₅₀ value of 79 nM .

HY-N1127R

Tricin (Standard)	Structural Classification Flavonoids Flavones Agrostidoideae Source classification Phenols Polyphenols Plants Triticum aestivum L.	CMV
Tricin (Standard) is the analytical standard of Tricin. This product is intended for research and analytical applications. Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

Species:	Human (8)
Tag:	His (3) Tag Free (3) GST (5) Flag (3)
Source:	Sf9 insect cells (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P701376

	CDK9-CCNT1 Heterodimer Protein, Human (Sf9) CDK9; CCNT1; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T1; CycT1; Cyclin-T	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P703558

	CDK9 Protein, Human (Sf9, GST) CDC2L4; TAK	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9 Protein, Human (Sf9, GST) is the recombinant human-derived CDK9, expressed by Sf9 insect cells , with GST labeled tag. The total length of CDK9 Protein, Human (Sf9, GST) is 372 a.a.,

HY-P701374

	CDK9-CCNK Heterodimer Protein, Human (Sf9) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701375

	CDK9-CCNK Heterodimer Protein, Human (Sf9, GST, FLAG) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (Sf9, GST, FLAG) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by Sf9 insect cells , with N-Flag, N-GST labeled tag.

HY-P702689

	CDK9-CCNT1 Protein, Human (sf9, GST, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT1 Protein, Human (sf9, GST, His) is the recombinant human-derived CDK9-CCNT1, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. ,

HY-P702690

	CDK9-CCNT2 Protein, Human (sf9, GST, Flag, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT2 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK9-CCNT2, expressed by Sf9 insect cells , with N-His, N-GST, N-Flag labeled tag. ,

HY-P701377

	CDK9-CCNT2 Heterodimer Protein, Human (Sf9) CDK9; CCNT2; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T2; CycT2	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT2 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT2 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P702924

	CDK9-CCNK Protein, Human (sf9, GST, Flag, His) CDC2L4; TAK; CPR4	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK9-CCNK, expressed by Sf9 insect cells , with C-6*His, N-GST, N-Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N1127S

Tricin-d6
Tricin-d₆ is the deuterium labeled Tricin[1]. Tricin is a natural flavonoid present in large amounts in Triticum aestivum. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7[2][3][4].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80614

	CDK9 Antibody TAK; C-2k; CTK1; CDC2L4; PITALRE	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	CDK9 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to CDK9. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.